Intuitive Surgical Inc header image

Intuitive Surgical Inc

ISRG

Equity

ISIN US46120E6023 / Valor 1631646

NASDAQ (2025-03-12)
USD 497.30+0.73%

Intuitive Surgical Inc
UMushroom community rating:

star star star star star
4.00 2 votes No rating yet
NegativeNeutralPositive

About company

Intuitive Surgical Inc is a global leader in the field of minimally invasive surgical solutions, with a focus on developing innovative robotic-assisted surgical systems and data generation services. With nearly three decades of experience, the company has revolutionized the way surgeries are performed, providing healthcare professionals with advanced tools to improve patient outcomes. Intuitive Surgical Inc's cutting-edge technology has the potential to transform healthcare systems around the world, making surgical procedures more precise, efficient, and effective.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (25.02.2025):

Revenue Growth

Intuitive Surgical Inc. reported a significant increase in revenue for the fourth quarter of 2024, reaching $2.41 billion. This marks a 25% growth compared to the $1.93 billion reported in the fourth quarter of 2023. The increase was primarily driven by a rise in da Vinci procedure volume and an expanded installed base of systems.

Net Income

For the fourth quarter of 2024, Intuitive Surgical Inc. achieved a GAAP net income of $686 million, or $1.88 per diluted share. This is an improvement from the $606 million, or $1.69 per diluted share, reported in the same quarter of the previous year. The non-GAAP net income for the quarter was $805 million, or $2.21 per diluted share, compared to $574 million, or $1.60 per diluted share, in the fourth quarter of 2023.

System Placements

Intuitive Surgical Inc. placed 493 da Vinci surgical systems in the fourth quarter of 2024, an increase from 415 systems in the fourth quarter of 2023. This includes 174 placements of the da Vinci 5 systems, contributing to the growth in the company's installed base, which reached 9,902 systems by the end of 2024.

Operating Income

The company's GAAP income from operations for the fourth quarter of 2024 rose to $735 million, compared to $450 million in the same period of 2023. On a non-GAAP basis, the income from operations increased to $928 million, up from $621 million in the fourth quarter of the previous year.

2025 Outlook

Looking ahead to 2025, Intuitive Surgical Inc. expects worldwide da Vinci procedures to grow by approximately 13% to 16%. The company also anticipates a non-GAAP gross profit margin in the range of 67% to 68% of net revenue, with operating expense growth projected between 10% and 15% for the year.

Summarized from source with an LLMView Source

Key figures

27.7%1Y
81.7%3Y
226%5Y

Performance

26.1%1Y
33.5%3Y
35.7%5Y

Volatility

Market cap

190513 M

Market cap (USD)

Daily traded volume (Shares)

2,558,661

Daily traded volume (Shares)

1 day high/low

529.02 / 521.03

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.00

2 votes
Performance:
starstarstarstarstar
4.00
Innovation:
starstarstarstarstar
4.50
Society:
starstarstarstarstar
4.00
Nature:
starstarstarstarstar
4.50
Robin Roten
Switzerland, 19 Oct 2022
star star star star star
Tej Ram Kumpakha
Switzerland, 12 Apr 2022
star star star star star
attractive revenue growth

EQUITIES OF THE SAME SECTOR

Herbalife Ltd
Herbalife Ltd Herbalife Ltd Valor: 2002103
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.47%USD 8.56
Novartis Inc
Novartis Inc Novartis Inc Valor: 1200526
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.64%CHF 96.31
Roche Holding Ltd
Roche Holding Ltd Roche Holding Ltd Valor: 1203211
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.90%CHF 325.40
Ypsomed Holding AG
Ypsomed Holding AG Ypsomed Holding AG Valor: 1939699
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.85%CHF 325.00
DocMorris Ltd
DocMorris Ltd DocMorris Ltd Valor: 4261528
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.76%CHF 21.12
aap Implantate AG
aap Implantate AG aap Implantate AG Valor: 57872565
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%EUR 1.80
Henry Schein Inc
Henry Schein Inc Henry Schein Inc Valor: 83527
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-4.09%USD 69.94
Bruker Corp
Bruker Corp Bruker Corp Valor: 1635622
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.32%USD 44.96
Elevance Health Inc
Elevance Health Inc Elevance Health Inc Valor: 26124340
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.61%USD 411.04
Stryker Corp
Stryker Corp Stryker Corp Valor: 974330
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.40%USD 363.84